faricimab
E238184
angiopoietin-2 inhibitor
biologic drug
bispecific monoclonal antibody
monoclonal antibody
ophthalmic drug
therapeutic antibody
vascular endothelial growth factor inhibitor
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
All labels observed (1)
| Label | Occurrences |
|---|---|
| faricimab canonical | 1 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
angiopoietin-2 inhibitor
ⓘ
biologic drug ⓘ bispecific monoclonal antibody ⓘ monoclonal antibody ⓘ ophthalmic drug ⓘ therapeutic antibody ⓘ vascular endothelial growth factor inhibitor ⓘ |
| administeredBy | ophthalmologist ⓘ |
| adverseEffect |
conjunctival hemorrhage
ⓘ
eye pain ⓘ increased intraocular pressure ⓘ vitreous floaters ⓘ |
| approvalYear | 2022 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToClass |
angiopoietin pathway inhibitors
ⓘ
anti-VEGF agents ⓘ |
| clinicalTrial |
LUCERNE
ⓘ
RHINE ⓘ TENAYA ⓘ YOSEMITE ⓘ |
| comparedWith | aflibercept ⓘ |
| contraindication |
active intraocular inflammation
ⓘ
ocular or periocular infection ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| dosingInterval | up to every 16 weeks in some patients ⓘ |
| hasATCCode | S01LA07 ⓘ |
| hasTradeName | Vabysmo ⓘ |
| indication |
treatment of diabetic macular edema
ⓘ
treatment of neovascular (wet) age-related macular degeneration ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| mechanismOfAction |
dual inhibition of VEGF-A and Ang-2 pathways
ⓘ
reduces vascular permeability in the retina ⓘ stabilizes retinal blood vessels ⓘ |
| molecularType | humanized IgG monoclonal antibody ⓘ |
| routeOfAdministration | intravitreal injection ⓘ |
| targetOrgan |
choroid
ⓘ
retina ⓘ |
| targets |
Ang-2
ⓘ
VEGF-A ⓘ angiopoietin-2 ⓘ vascular endothelial growth factor A ⓘ |
| therapeuticArea |
ophthalmology
ⓘ
retinal diseases ⓘ |
| usedFor |
diabetic macular edema
ⓘ
macular edema secondary to retinal vein occlusion ⓘ neovascular age-related macular degeneration ⓘ wet age-related macular degeneration ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.